Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Memo Therapeutics AG
Headquarters: Zurich, Switzerland
Website: https://memo-therapeutics.com/...
Year Founded: 2012
Status: Private
BioCentury | Nov 5, 2024
Management Tracks
Alan Bash named president of Carvykti at Legend
Plus: CureVac hires Axel Malkomes as CFO; new CEOs at Coya, Libra; and updates from 4BIO, Memo and Alltrna
BioCentury | Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Jul 10, 2024
Management Tracks
Pfizer seeking successor as Dolsten prepares to step down from R&D role
Plus: Lexicon, Pathios and Xeris name new CEOs, and updates from Jazz, AgomAb, VectorY, eTheRNA and more
BioCentury | May 9, 2024
Finance
Venture report: Big rounds for Bluejay, Attovia and Zenas
Strong fundraising week also included launches by Prologue and Commit, plus raises by Aardvark, Memo and OverT
BioCentury | Nov 17, 2023
Management Tracks
Memo names Erik van den Berg as CEO
Plus: Martin Murphy stepping down as Syncona chair, and updates from Red Tree, OMass and Anagenex
BioCentury | Nov 7, 2023
Finance
Nov. 6 Financial Roundup: Cargo aims for $300M NASDAQ listing
Plus: Terremoto raises B round and updates from Engine, Memo, ImmuXell, Longbio and Ausper
BioCentury | Nov 10, 2020
Finance
Nov. 9 Quick Takes: Biogen sheds $14B in value; plus Ambrx’s 200M round, Decibel’s series D and more
Biogen tumbles after aducanumab panelAfter Friday’s FDA advisory committee meeting for Alzheimer’s therapy Aduhelm aducanumab, shares of Biogen Inc. (NASDAQ:BIIB) sank $92.64 (28%) to
Items per page:
1 - 8 of 8